{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:08:55Z","timestamp":1784243335317,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fund for Innovation and Clinical Research (FIKO), Ghent University Hospital, Ghent, Belgium"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Janus kinase inhibitors (JAKi) are successfully used for the treatment of refractory systemic autoimmune diseases. However, JAK-inhibition is known to increase the risk of infection. Herpes Zoster reactivation is the most recognised infectious complication of JAKi. Events involving herpes simplex are reported less frequently than zoster and have generally received less attention. Our goal is to raise awareness of JAKi-associated herpes simplex keratitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This paper describes four cases of severe herpes simplex keratitis in patients treated with oral JAK inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All patients presented with a geographic epithelial keratitis. One patient presented with bilateral involvement. Viral PCR of corneal swabs demonstrated the presence of HSV-1 and absence of VZV in all patients, confirming the diagnosis of herpes simplex keratitis. The patients were treated with various oral JAK inhibitors (baricitinib, upadacitinib, ruxolitinib and abrocitinib), which demonstrated an underlying class effect. Finally, the time lapse also supports an association between the use of oral JAKi and herpetic keratitis, as evidenced by the development of HSV1-related keratitis shortly after the start of oral JAKi in 3 of the 4 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinicians should be aware of the association between the use of oral JAKi and herpes simplex keratitis. Not only can HSV1-related keratitis manifest itself in this patient group as a severe geographic keratitis, it can also occur bilaterally. An urgent ophthalmological evaluation is recommended for patients taking oral JAKi who present with unilateral or bilateral red, painful eye(s), even in the absence of periocular signs of Herpes Zoster infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12348-026-00601-1","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:21:00Z","timestamp":1779531660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PCR-confirmed severe geographic HSV-1 keratitis associated with systemic JAK inhibitor therapy"],"prefix":"10.1186","volume":"16","author":[{"given":"Dimitri","family":"Roels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke O.","family":"Kreps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabeau","family":"Houben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Delie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Lapeere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart P.","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Claerhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Kerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"5","key":"601_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jaci.2024.07","volume":"154","author":"SYC Tsai","year":"2024","unstructured":"Tsai SYC, Phipatanakul W, Hawryluk EB, Oyoshi MK, Schneider LC, Ma KSK (2024) Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study. J Allergy Clin Immunol 154(5):1195\u20131203e3. https:\/\/doi.org\/10.1016\/j.jaci.2024.07.019. PubMed PMID: 39097196","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"601_CR2","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","volume":"152","author":"AWL Chu","year":"2023","unstructured":"Chu AWL, Wong MM, Rayner DG, Guyatt GH, D\u00edaz Martinez JP, Ceccacci R et al (2023) Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol 152(6):1470\u20131492 .029 PubMed PMID: 37678577","journal-title":"J Allergy Clin Immunol"},{"key":"601_CR3","doi-asserted-by":"publisher","unstructured":"Hecquet S, Valnet Rabier MB, Lepelley M, Verhoeven F, Delbosc B, Avouac J et al (2023) Ophthalmic adverse events under tofacitinib and baricitinib: case analysis of the European Pharmacovigilance Database. Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2022.105483. PubMed PMID: 36370964","DOI":"10.1016\/j.jbspin.2022.105483"},{"key":"601_CR4","doi-asserted-by":"publisher","first-page":"II24","DOI":"10.1093\/rheumatology\/keaa","volume":"60","author":"B Clarke","year":"2021","unstructured":"Clarke B, Yates M, Adas M, Bechman K, Galloway J (2021) The safety of JAK-1 inhibitors. Rheumatol (United Kingdom) 60:II24\u201330. https:\/\/doi.org\/10.1093\/rheumatology\/keaa895 PubMed PMID: 33950230","journal-title":"Rheumatol (United Kingdom)"},{"issue":"9","key":"601_CR5","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S et al (2021) Efficacy and Safety of Upadacitinib vs Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol 157(9):1047\u20131055. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023 PubMed PMID: 34347860","journal-title":"JAMA Dermatol"},{"key":"601_CR6","doi-asserted-by":"publisher","unstructured":"Chen M, Ke C, Huang Y (2024) Herpes virus reactivation induced by abrocitinib: a real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Diagn Microbiol Infect Dis 110(4). https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116546 PubMed PMID: 39340963","DOI":"10.1016\/j.diagmicrobio.2024.116546"},{"key":"601_CR7","doi-asserted-by":"publisher","unstructured":"Ida T, Furuta S, Takayama A, Tamura J, Hayashi Y, Abe K et al (2023) Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis. RMD Open 9(1). https:\/\/doi.org\/10.1136\/rmdopen-2022-002795 PubMed PMID: 36593080","DOI":"10.1136\/rmdopen-2022-002795"},{"key":"601_CR8","doi-asserted-by":"publisher","unstructured":"Dunn R, Long E, Gagnon LL, Harrison C, Yang Y, O\u2019Sullivan J (2025) Treatment of myeloproliferative neoplasms with Janus Kinase inhibitors: a meta-analysis of cardiovascular safety. EJHaem 6(1). https:\/\/doi.org\/10.1002\/jha2.70000","DOI":"10.1002\/jha2.70000"},{"key":"601_CR9","doi-asserted-by":"publisher","unstructured":"Schramm do Nascimento MA, Filho SRC, Miranda MD, de Mendes AEM Paula e Silva Carneiro Mendes, de Souza G, Borba HHL (2025) Ruxolitinib in the treatment of acute corticosteroid-refractory graft-versus-host disease: a scoping review. Transplant Cell Ther 31(8):569. https:\/\/doi.org\/10.1016\/j.jtct.2025.04.018.\u00a0PubMed PMID: 40345439","DOI":"10.1016\/j.jtct.2025.04.018"},{"key":"601_CR10","doi-asserted-by":"publisher","unstructured":"Calvo-R\u00edo V, S\u00e1nchez-Bilbao L, \u00c1lvarez-Reguera C, Casta\u00f1eda S, Gonz\u00e1lez-Maz\u00f3n I, Demetrio-Pablo R et al (2022) Baricitinib in severe and refractory peripheral ulcerative keratitis: a case report and literature review. Ther Adv Musculoskelet Dis 14. https:\/\/doi.org\/10.1177\/1759720X221137126","DOI":"10.1177\/1759720X221137126"},{"key":"601_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2324400","author":"J Wen","year":"2021","unstructured":"Wen J, Hu H, Chen M, Yang H, Zhao Y, Liu Y (2021) Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review. J Immunol Res Hindawi Ltd. https:\/\/doi.org\/10.1155\/2021\/2324400 PubMed PMID: 34966823","journal-title":"J Immunol Res Hindawi Ltd"},{"key":"601_CR12","doi-asserted-by":"publisher","unstructured":"Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: From interferons to cytokines. J Biol Chem 20059\u201320063. https:\/\/doi.org\/10.1074\/jbc.R700016200 \u00a0PubMed PMID: 17502367","DOI":"10.1074\/jbc.R700016200"},{"key":"601_CR13","doi-asserted-by":"crossref","unstructured":"Danastas K, Miranda-Saksena M, Cunningham AL (Jul 21 2020) Herpes simplex virus type 1 interactions with the interferon system. Int J Mol Sci","DOI":"10.3390\/ijms21145150"},{"key":"601_CR14","doi-asserted-by":"publisher","unstructured":"Raftery N, Stevenson NJ (2017) Advances in anti-viral immune defence: Revealing the importance of the IFN JAK\/STAT pathway. Cell Mol Life Sci. Birkhauser AG, pp 2525\u20132535. https:\/\/doi.org\/10.1007\/s00018-017-2520-2 PubMed PMID: 28432378","DOI":"10.1007\/s00018-017-2520-2"},{"key":"601_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00015","author":"NJ Bigley","year":"2014","unstructured":"Bigley NJ (2014) Complexity of interferon-\u03b3 interactions with HSV-1. Frontiers in Immunology. Front Res Foundation. https:\/\/doi.org\/10.3389\/fimmu.2014.00015","journal-title":"Front Res Foundation"},{"issue":"22","key":"601_CR16","doi-asserted-by":"publisher","first-page":"11541","DOI":"10.1128\/jvi.76.22.11541-11550","volume":"76","author":"B Sainz","year":"2002","unstructured":"Sainz B, Halford WP (2002) Alpha\/Beta Interferon and Gamma Interferon Synergize To Inhibit the Replication of Herpes Simplex Virus Type 1. J Virol 76(22):11541\u201311550. https:\/\/doi.org\/10.1128\/jvi.76.22.11541-11550.2002 PubMed PMID: 12388715","journal-title":"J Virol"},{"issue":"9","key":"601_CR17","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/infdis\/jiac040","volume":"225","author":"M Krzyzowska","year":"2022","unstructured":"Krzyzowska M, Jarneborn A, Thorn K, Eriksson K, Jin T (2022) Tofacitinib Treatment in Primary Herpes Simplex Encephalitis Interferes With Antiviral Response. J Infect Dis 225(9):1545\u20131553. https:\/\/doi.org\/10.1093\/infdis\/jiac040 PubMed PMID: 35217873","journal-title":"J Infect Dis"},{"key":"601_CR18","doi-asserted-by":"publisher","unstructured":"Mansilla-Polo M, Morgado-Carrasco D (2024) Biologics versus JAK inhibitors. Part II: risk of infections. A narrative review. Dermatol Ther Adis, pp 1983\u20132038. https:\/\/doi.org\/10.1007\/s13555-024-01203-2","DOI":"10.1007\/s13555-024-01203-2"},{"key":"601_CR19","doi-asserted-by":"publisher","unstructured":"Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Tha\u00e7i D, Torrelo A et al (2023) Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: An updated integrated analysis of eight clinical trials. J Dermatolog Treat 34(1). https:\/\/doi.org\/10.1080\/09546634.2022.2161812 PubMed PMID: 36546346","DOI":"10.1080\/09546634.2022.2161812"},{"issue":"2","key":"601_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","volume":"81","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Nash P, Yamaoka K, Mysler E, Khan N, Camp HS et al (2022) Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Ann Rheum Dis 81(2):206\u2013213. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220822 PubMed PMID: 34615638","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"601_CR21","first-page":"663","volume":"26","author":"Q Luo","year":"2021","unstructured":"Luo Q, Xiao Z, Peng L (2021) Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis. Hematol (United Kingdom) 26(1):663\u2013669 2021.1967256 PubMed PMID: 34493151","journal-title":"Hematol (United Kingdom)"},{"issue":"3","key":"601_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S0161-6420(","volume":"110","author":"PMF Souza","year":"2003","unstructured":"Souza PMF, Holland EJ, Huang AJW (2003) Bilateral Herpetic Keratoconjunctivitis. Ophthalmology 110(3):625\u2013629. https:\/\/doi.org\/10.1016\/S0161-6420(02)01769-4 PubMed PMID: 12623833","journal-title":"Ophthalmology"},{"key":"601_CR23","doi-asserted-by":"publisher","unstructured":"Azher TN, Yin XT, Tajfirouz D, Huang AJ, Stuart PM (2017) Herpes simplex keratitis: Challenges in diagnosis and clinical management. Clin Ophthalmol 185\u2013191. https:\/\/doi.org\/10.2147\/OPTH.S80475","DOI":"10.2147\/OPTH.S80475"},{"key":"601_CR24","doi-asserted-by":"publisher","unstructured":"Chaloulis SK, Mousteris G, Tsaousis KT (2022) Incidence and risk factors of bilateral herpetic keratitis: 2022 update. Trop Med Infect Dis. https:\/\/doi.org\/10.3390\/tropicalmed7060092","DOI":"10.3390\/tropicalmed7060092"},{"issue":"5","key":"601_CR25","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/09273948.2025.2503327","volume":"33","author":"SB Mishra","year":"2025","unstructured":"Mishra SB, Kawali A, Mahendradas P, Shetty R (2025) Disseminated Varicella-Zoster Virus-Associated Acute Retinal Necrosis in a Post-Bone Marrow Transplant Patient. Ocul Immunol Inflamm 33(5):718\u2013720 2025.2503327 PubMed PMID: 40346926","journal-title":"Ocul Immunol Inflamm"},{"key":"601_CR26","doi-asserted-by":"publisher","unstructured":"Adam DN, Gooderham MJ, Beecker JR, Hong CH, Jack CS, Jain V et al (2023) Expert consensus on the systemic treatment of atopic dermatitis in special populations. J Eur Acad Dermatol Venereol 1135\u20131148. https:\/\/doi.org\/10.1111\/jdv.18922 PubMed PMID: 36695072","DOI":"10.1111\/jdv.18922"},{"issue":"5","key":"601_CR27","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.4049\/jimmunol.1502366","volume":"196","author":"L Jing","year":"2016","unstructured":"Jing L, Laing KJ, Dong L, Russell RM, Barlow RS, Haas JG et al (2016) Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses. J Immunol 196(5):2205\u20132218. https:\/\/doi.org\/10.4049\/jimmunol.1502366 PubMed PMID: 26810224","journal-title":"J Immunol"},{"key":"601_CR28","doi-asserted-by":"publisher","unstructured":"Malik S, Sah R, Ahsan O, Muhammad K, Waheed Y (2023) Insights into the novel therapeutics and vaccines against herpes simplex virus. Vaccines. MDPI. https:\/\/doi.org\/10.3390\/vaccines11020325","DOI":"10.3390\/vaccines11020325"},{"key":"601_CR29","doi-asserted-by":"publisher","unstructured":"Chiu C, McCausland M, Sidney J, Duh FM, Rouphael N, Mehta A et al (2014) Broadly reactive human CD8 T cells that recognize an epitope conserved between VZV, HSV and EBV. PLoS Pathog 10(3). https:\/\/doi.org\/10.1371\/journal.ppat.1004008 PubMed PMID: 24675761","DOI":"10.1371\/journal.ppat.1004008"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-026-00601-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-026-00601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-026-00601-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:40:47Z","timestamp":1784241647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12348-026-00601-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["601"],"URL":"https:\/\/doi.org\/10.1186\/s12348-026-00601-1","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and an institutional ethics review board approval was obtained at Ghent University Hospital (CR-2025-0010). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"36"}}